医学
接种疫苗
癌症
宫颈癌
造谣
欧洲联盟
心理干预
乙型肝炎病毒
乙型肝炎
子宫颈
公共卫生
疾病
重症监护医学
免疫学
家庭医学
人类免疫缺陷病毒(HIV)
疾病负担
丙型肝炎
肝癌
淋病
环境卫生
干预(咨询)
作者
Catharina J. Alberts,Paul Bloem,Silvia de Sanjosé,Sophie Grabar,M ̄arcis Leja,Peter Malfertheiner,Mojca Matičič,Francis Mégraud,Francesco Negro,Martyn Plummer,Maarten Schim van der Loeff,Graciela Balbin,Josefina Salazar,Hajo Zeeb,Ariadna Feliu,Erica D'Souza,David Ritchie,Carolina Espina,Silvia Franceschi
标识
DOI:10.1002/1878-0261.70172
摘要
The main infections that cause cancer in the European Union (EU) are Helicobacter pylori (H. pylori), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Altogether, in 2022, these infections accounted for ~ 5% of all cancers in the EU, mainly of the stomach, cervix uteri and liver. The largest burden of infection-caused cancers was found in the south of the EU and near the eastern border. Substantial progress in the efficacy of interventions against these infections has been made since the release of the 4th edition of the European Code Against Cancer in 2015. Cancers due to infections can increasingly be prevented by prophylactic vaccines (HPV and HBV) and/or prompt diagnosis and treatment that can either cure (HCV and H. pylori) or slow down the infection (HBV and HIV), thus substantially reducing disease risk. Tools to tackle carcinogenic infections are also increasingly accessible and affordable in the EU, but their implementation is slow. Public awareness, political will and cost-effective protocols are necessary to establish large programmes of vaccination or testing and treatment. Progress monitoring, as well as avoiding disinformation and stigma, is crucial to ensure that advances in medical progress are fully leveraged. The recently published 5th edition of the European Code Against Cancer therefore recommends: (1) vaccinate girls and boys against HBV and HPV at the age recommended in your country; (2) take part in testing and treatment for HBV and HCV, HIV and H. pylori, as recommended in your country.
科研通智能强力驱动
Strongly Powered by AbleSci AI